Equities

Profile data is unavailable for this security.

About the company

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

  • Revenue in CHF (TTM)48.39bn
  • Net income in CHF6.44bn
  • Incorporated1996
  • Employees119.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVN:VTX since
announced
Transaction
value
Advanced Accelerator Applications SARumoured27 Sep 201727 Sep 2017Rumoured2.59%--
Encore Vision IncAnnounced20 Dec 201620 Dec 2016Announced15.32%--
Ziarco Pharma LtdDeal completed16 Dec 201616 Dec 2016Deal completed15.87%--
Amneal Pharmaceuticals LLCRumoured14 Nov 201614 Nov 2016Rumoured17.31%--
Data delayed at least 15 minutes, as of Oct 23 2017 12:18 BST.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.